Hartmut Ehrlich News Today

Abivax expects top-line data from a trial testing its ABX464 anti-infammatory therapy for UC by year's end, with plans to launch a CD trial by mid-2020.

15.11.2022 - EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting 15.11.2022 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. ABIVAX ...

DGAP-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2022 financial results and operations update 15....

DGAP-News: ABIVAX / Key word(s): Half Year ResultsAbivax presents first-half 2022 financial results and operations update 15.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE Obefazimod global piv...

DGAP-News: ABIVAX / Key word(s): MiscellaneousAbivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting 10.06.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary ge...

10.06.2022 - DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting 10.06.2022 / 18:00 The issuer is solely responsible for the content of this announcement. Abivax ...

The three top executives from Abivax SA (OTCMKTS:AAVXF) explain the development of the ulcerative colitis treatment.

Press release content from Accesswire. The AP news staff was not involved in its creation.

16.03.2022 Abivax reports 2021 financial results and operations update | ABIVAX | News | Nachricht | Mitteilung

16.03.2022 Abivax reports 2021 financial results and operations update | ABIVAX | News | Nachricht | Mitteilung